Techniques and platforms used for immunoassays vary greatly based on the target, treatment type, and desired endpoints. Read our blog to figure out which one is best for your clinical trial needs. https://hubs.ly/Q02F0jVX0 #translationalresearch #immunoassays #drugdevelopment #biomarkers
Precision For Medicine’s Post
More Relevant Posts
-
Digital Health Strategist & Researcher | Mental Health Advocate & Educator | Change Leadership Trainer, Facilitator and Coach
Continuous Behavior Measurement has 4 novel use cases for biopharma clinical trials and patient support. Check out our blog post on this topic and request a Vira demo today. #measurementbasedcare #valuebasedcare #realworldevidence #realworlddata #continuousbehaviormeasurement
To view or add a comment, sign in
-
As we approach Rare Diseases Day, TMC are running a webinar on how the Medical Services approach needs to be different for orphan and rare diseases. The Webinar is on Thursday and the link to register is in the attached post. #tmcpharma
Only two days to go... This Thursday, we're running an exclusive webinar: 'Exploring the differences in medical services for rare diseases'. Led by Marcelo Alexandre Costa Vaz, Lucy Fulford-Smith and Dr Mehrnaz Tadayon, the session will explore valuable insights into the scope of medical services during a drug's life cycle — with opportunities to engage with our esteemed panel of experts. This is a must-attend for anyone representing the pharma and biotech industry. Register your attendance below! #Webinar #MedicalServices #BiotechIndustry https://lnkd.in/eGcTUAXz
To view or add a comment, sign in
-
🌟 🌟 Dr. Tianwei Li wrote #HighlyCitedPaper "#The Therapeutic Potential and Clinical Significance of Exosomes as Carriers of Drug Delivery System" You can find it at: https://lnkd.in/gUfng2M5
To view or add a comment, sign in
-
Cirrhotic MASH brings unique challenges. Diagnosing its metabolic origins in advanced cirrhosis is tough. This affects traditional endpoints for drug efficacy. How common are liver-related events in MASH cirrhosis? How does this impact patient management and trial design? Join us at EASL #SLDSummit for insights. 🌟 🔗 http://easl.eu/sld2023
To view or add a comment, sign in
-
Editor/Founder The Pharmaceutical Marketing Group - Executive Director at Clinician Burnout Foundation
📊 Data-driven insights can help pharma reach the right patients and combat therapeutic inertia. Find out how in this exclusive Reuters Events whitepaper sponsored by Wefight, featuring experts from top pharma and patient organizations. Get your copy now: https://bit.ly/46qKrrr #DataDrivenHealthcare #PharmaInsights #PatientEngagement
To view or add a comment, sign in
-
Have you used #IPC’s Biosimilars Resource Page? This page lists resources to provide background information on biosimilars, suggests practical guidance on communicating biosimilar benefits to patients, and presents real-world clinical scenarios of psoriasis management with biosimilars. Try our Resource Page here: https://lnkd.in/eZJUpY8V #IPCCommunity #PsoriasisResources #PsoriasisNews
To view or add a comment, sign in
-
Strategic Clinical Operations Leader | Veeva Vault TMF Specialist | Driving Quality and Compliance in Clinical Research
Based on the critical quality for the upcoming ICH E6 (R3), this is the first step your site can take toward the implementation. #E6 #ICHE6 #clinicalresearch #clinicaltrials #clinicaltrial #clinicaldatamanagement
The data you collect must be defensible and complete, and biological samples represent a critical source of that data. Therefore, to successfully execute a #clinicaltrial, the sample management process also needs to be defensible and complete. It is crucial to have visibility into the entire sample journey, as it demonstrates protocol compliance and sample traceability. Lost or mishandled samples can significantly impact research sites, patients, data integrity, and study timelines. Unfortunately, the current approach to overseeing study progress and managing risks during sample collection, processing, storage, shipping, and receipt is inconsistent at best. Limited visibility and reliance on reactive strategies both lead to gaps in sample traceability and non-standardized processes. This makes balancing sample management with available resources and budget an inevitable challenge. So, what can you do? — Know the hidden regulatory risks — Create standardized and systematic processes — Encourage collaboration and visibility — Pick the right technology for your study and sites — Build documentation for consistent and streamlined reconciliation — Be prepared to handle complications Learn more about how to employ these sample management best practices in our latest white paper: https://hubs.la/Q01Zsxb10 #samplemanagement #biospecimen #clinicaldata #clinicalresearch #cellandgene #oncology
Ultimate Guide to Managing Biological Samples for Sponsors
slopeclinical.com
To view or add a comment, sign in
-
Unsure how to transition your clinical trial assay to companion diagnostic (CDx)? Our experts can help. Learn more here 👉 https://bit.ly/3qALZ2d #CellCarta #ClinicalTrials #PrecisionMedicine
Discover how CellCarta can support your CDX projects
https://cellcarta.com
To view or add a comment, sign in
114,240 followers